Picovax (IPV-Al AJV)
/ AJ Vaccines
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
September 07, 2022
Persistence of protective anti-poliovirus antibody levels in 4-year-old children previously primed with Picovax®, a trivalent, aluminium-adjuvanted reduced dose inactivated polio vaccine.
(PubMed, Vaccine)
- P4 | "The present trial demonstrated that the primary vaccination with an aluminium-adjuvanted reduced dose IPV induced a persistent immune memory as evidenced by the robust anamnestic response when the subjects were re-exposed to the antigen 2.5 years after the last dose. Thus, the IPV-Al is an efficient and safe addition to increase the availability of inactivated polio vaccines globally. (ClinicalTrials.gov reg no. NCT04448132)."
Journal
June 22, 2021
Evaluation of Persistence of Immunity in 4-year-old Children Previously Immunised With IPV-Al AJV (Picovax®)
(clinicaltrials.gov)
- P4; N=163; Completed; Sponsor: AJ Vaccines A/S; Enrolling by invitation ➔ Completed; N=300 ➔ 163; Trial completion date: Mar 2022 ➔ May 2021; Trial primary completion date: Sep 2021 ➔ May 2021
Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date • Infectious Disease
November 30, 2020
Evaluation of Persistence of Immunity in 4-year-old Children Previously Immunised With IPV-Al AJV (Picovax®)
(clinicaltrials.gov)
- P4; N=300; Enrolling by invitation; Sponsor: AJ Vaccines A/S; Not yet recruiting ➔ Enrolling by invitation
Clinical • Enrollment open • CNS Disorders • Infectious Disease
1 to 3
Of
3
Go to page
1